UNSPSC 51111740: Daunorubicin hydrochloride

This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UD984I04LZ, chemically known as 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, radical ion(1-), (8s,10s)- but generally known as daunorubicin hydrochloride, which bears US NIH Compound Identifier 2958.

UNSPSC 51111740 Daunorubicin hydrochloride is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally describes daunorubicin hydrochloride, a chemotherapy drug used in oncology treatment, yet the four recent opportunities posted under this code—ranging from naloxone and drug deactivation systems to generic pharmaceuticals and fire department medical supplies—do not involve daunorubicin or match its therapeutic class. State and local governments do procure oncology pharmaceuticals, but this code's recent activity reflects a tagging mismatch rather than genuine demand for the named product. The issuing bodies in the dataset span a county health department (Seminole County, Florida), a state health agency (Texas HHS Commission), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (MMCAP serving Minnesota, Oregon, and member jurisdictions), indicating that pharmaceutical procurement occurs across multiple jurisdiction types and governance structures.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon based on the recent opportunities. Seminole County posted an IFB for naloxone and drug deactivation systems due July 26, 2023 (note: the due date is misaligned with the posted date of June 30, 2026, suggesting a data error in the source). The Texas HHS Commission issued an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs. The City of Tampa released an IFB for medical and first aid supplies on March 25, 2026, with a response deadline of March 13, 2026 (another apparent date inconsistency), with an estimated contract value of $700,000 and a small local business enterprise set-aside with a 5 percent bid discount. MMCAP posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026. Because the code shows no genuine recent activity for daunorubicin hydrochloride specifically, firms should investigate whether the code assignment reflects procurement-office error or whether opportunities under this code are being re-tagged at award. Pursuing this code in its current state carries material execution risk.